CMS grants Spectrum permanent J-Code for Rolvedon injection

Spectrum Pharmaceuticals announced that a permanent J-code, J1449, has been issued for ROLVEDON or eflapegrastim-xnst Injection by the U.S. Centers for Medicare & Medicaid Services CMS effective as of April 1 . "This is an important milestone in the ROLVEDON launch. A permanent J-code will enable a more efficient and predictable reimbursement in the outpatient setting. The combination of a permanent J-code on April 1, 2023 and ROLVEDON’S inclusion in the National Comprehensive Cancer Network Supportive Care Guidelines (NCCN Guidelines announced on December 6 are key elements in establishing brand awareness and building customer confidence in our novel product," said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. J-codes are permanent reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like ROLVEDON that are administered by a physician. Claims submission and documentation are simplified with a permanent J-code, facilitating and streamlining the billing and reimbursement process.